Lung Cancer News and Research RSS Feed - Lung Cancer News and Research Twitter

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
Olympus' surgical products named finalists for ATA award

Olympus' surgical products named finalists for ATA award

Olympus, a global technology leader in delivering innovative diagnostic and therapeutic solutions in Medical and Surgical procedures, among other core businesses, announced today that two of its surgical products have been named finalists for an American Technology Award (ATA) in the Health and Medical Technologies category: ENDOEYE FLEX 3D and THUNDERBEAT. [More]
Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

CANCER RESEARCH UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer. [More]

Researchers create clinical trial for patients with advanced lung cancer

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer. [More]
Protein expression predicts postop NSCLC recurrence, survival

Protein expression predicts postop NSCLC recurrence, survival

US-based researchers have identified a panel of 12 proteins that may help predict overall survival and the risk of recurrence in patients treated with surgery for non-small-cell lung cancer. [More]

Urologists offer new tool for visualizing, monitoring prostate in men with greater accuracy

Urologists at Rush University Medical Center are the first in Chicago to offer a powerful new tool for visualizing and monitoring the prostate in men who have high prostate-specific antigen (PSA) levels and in detecting prostate cancer more accurately. [More]
Three-gene test may aid earlier lung cancer detection

Three-gene test may aid earlier lung cancer detection

Methylation of three genes may help with the early diagnosis of non-small-cell lung cancer, research suggests. [More]
Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Phase I study findings suggest the investigational drug ceritinib is effective in patients with advanced non-small-cell lung cancer with anaplastic lymphoma kinase gene rearrangement, even in those who develop resistance to crizotinib. [More]

Amrubicin regimen inferior to irinotecan for extensive SCLC

Irinotecan plus cisplatin remains the gold standard for Japanese patients with extensive small-cell lung cancer, say researchers, after amrubicin plus cisplatin failed to improve survival in their randomised phase III trial. [More]
Targeting enzyme responsible for glucose metabolism halts tumor growth, say researchers

Targeting enzyme responsible for glucose metabolism halts tumor growth, say researchers

Cancer cells generate energy differently than normal cells, a characteristic that helps them to survive and metastasize. A major goal in the field of cancer metabolism is to find ways to overcome this survival advantage. [More]
Tumor-suppressing protein acts as dimmer switch to dial down gene expression

Tumor-suppressing protein acts as dimmer switch to dial down gene expression

A tumor-suppressing protein acts as a dimmer switch to dial down gene expression. It does this by reading a chemical message attached to another protein that's tightly intertwined with DNA, a team led by scientists at The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2014. [More]
Clinical Research Forum announces winners of third annual Top 10 Clinical Research Achievement Awards

Clinical Research Forum announces winners of third annual Top 10 Clinical Research Achievement Awards

The Clinical Research Forum has announced the winners of its third annual Top 10 Clinical Research Achievement Awards. The winning projects represent the outstanding examples of research projects that benefit the health and well-being of the general public. [More]
AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test. [More]

Researchers find that cancer gene require copper to promote tumor growth

Drugs used to block copper absorption for a rare genetic condition may find an additional use as a treatment for certain types of cancer, researchers at Duke Medicine report. [More]

CAP receives CDC grants to improve adoption of evidence-based laboratory testing guidelines

The College of American Pathologists (CAP), the world's largest organization of board-certified pathologists, has been awarded two grants from the Centers for Disease Control and Prevention (CDC). [More]
Study identifies two cell surface receptors that may be responsible for spread of lung cancer

Study identifies two cell surface receptors that may be responsible for spread of lung cancer

Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute. [More]
Researchers identify novel compound effective against drug-resistant lung cancer

Researchers identify novel compound effective against drug-resistant lung cancer

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective. [More]
Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. [More]

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. [More]

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). [More]
Women who had radiotherapy for breast cancer may have increased risk of lung tumour

Women who had radiotherapy for breast cancer may have increased risk of lung tumour

Women who have radiotherapy for breast cancer have a small but significantly increased risk of subsequently developing a primary lung tumour, and now research has shown that this risk increases with the amount of radiation absorbed by the tissue. [More]